Abstract

Purpose
The role of The Clinical Treatment Score post-5 years (CTS5) in male breast cancer (MBC) remains unclear. This study aimed to investigate the characteristics and prognosis of CTS5 between MBC and female breast cancer (FBC).
Materials and Methods
Patients diagnosed with human epidermal growth factor receptor 2 negative /estrogen receptor-positive breast cancer between 2010 and 2015 were identified from the SEER database. The chi-square test, Kaplan-Meier analysis, and multivariate Cox proportional hazard model were used for statistical analysis.
Results
This study included 169869 patients, comprising 168422 (99.1%) FBC and 1447 (0.9%) MBC patients. More MBC patients had intermediate risk (IR)/high risk (HR) disease compared to FBC patients (17.7% vs. 8.7%, p<0.001). MBC patients had an inferior overall survival (OS) but similar breast cancer-specific survival compared to those with FBC. Sensitivity analyses showed that gender was an independent prognostic factor associated with OS but not BCSS in both the low-risk (LR) and IR/HR cohorts. Those with MBC exhibited significantly worse OS (p<0.001) than FBC patients in both cohorts. In MBC patients, those with IR/HR disease had significantly worse OS (P<0.001) and BCSS (p<0.001) compared to those with LR disease. For FBC patients, the IR/HR group had also significantly worse OS (p<0.001) and BCSS (p<0.001) compared to the LR group.
Conclusion
Our findings highlight critical differences in clinical characteristics, treatment patterns, and outcomes between MBC and FBC, suggesting the need for gender-tailored approaches in breast cancer management.

• Keywords: Breast neoplasms, CTS5, Male, Female, Survival